Journal
EUROPEAN JOURNAL OF CANCER
Volume 43, Issue 4, Pages 676-682Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2006.10.021
Keywords
LRIG; EGFR; ErbB; tumour suppressor; receptor tyrosine kinase
Categories
Ask authors/readers for more resources
The leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins are newly discovered negative regulators of growth factor signalling and proposed tumour suppressors. They antagonise signalling by interacting with growth factor receptors and by enhancing their ubiquitylation and degradation. Data on the expression of LRIG in human cancer have recently begun to accumulate; however, not all data appear consistent with the notion that the LRIG proteins always function as tumour suppressors. in the present review, we argue that the LRIG proteins could be double-edged swords, promoting or suppressing human cancer depending on cellular context. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available